TSW
PBYI icon

Thompson Siegel & Walmsley’s Puma Biotechnology PBYI Stock Holding History

Thompson Siegel & Walmsley’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-16,500
Closed -$640K – 769
2019
Q1 		$640K Buy
+16,500
New +$504K 0.01% 310

Other funds holding PBYI

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Thompson Siegel & Walmsley's PBYI Position: Q2 2019 in Review

Thompson Siegel & Walmsley sold out of Puma Biotechnology (PBYI) in Q2 2019, closing a stake of 16,500 shares — an estimated $640K sold.

Thompson Siegel & Walmsley first reported a position in PBYI in Q1 2019 and held it in 1 quarter. The position peaked at $640K in Q1 2019. 139 funds tracked by Wall St. Rank hold PBYI as of Q2 2019.

  • Thompson Siegel & Walmsley reported no remaining Puma Biotechnology position as of Q2 2019 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 16,500 Puma Biotechnology shares in Q2 2019, an estimated $640K.
  • Thompson Siegel & Walmsley first reported a position in Puma Biotechnology in Q1 2019 and held it in 1 quarter.
  • Thompson Siegel & Walmsley's Puma Biotechnology position peaked at $640K in Q1 2019.
  • 139 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2019.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2019, filed 12 Aug 2019.